Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

Video content above is prompted by the following:

ZUMA-5 5-Year Follow-Up: Axicabtagene Ciloleucel in R/R iNHL

Key Findings

Long-Term Efficacy Highlights

• Sustained durable responses observed in patients with R/R iNHL
• Demonstrates the potential of CAR T-cell therapy as a transformative treatment approach
• Continued efficacy and manageable long-term safety profile beyond initial clinical trial period

Durability of Response

• Maintained complete response rates at 5 years
• Consistent progression-free survival in heavily pretreated patient population
• Suggests CAR T-cell therapy can provide long-term disease control in challenging iNHL cases

Clinical Implications

Treatment Strategy Considerations

• CAR T-cell therapy emerges as a potentially curative option for patients with multiple prior lines of therapy.
• Particularly promising for patients with limited treatment alternatives
• Supports earlier consideration of CAR T-cell therapy in the treatment algorithm for R/R iNHL

Patient Selection

• Most beneficial for patients with:
• Multiple prior treatment lines

• Chemotherapy-resistant disease

• Good performance status

• No significant comorbidities limiting CAR T-cell therapy eligibility

Practical Takeaways

• Long-term data reinforce the potential of axicabtagene ciloleucel as a meaningful treatment option.
• Encourages more aggressive consideration of CAR T-cell therapy earlier in the treatment paradigm
• Highlights the importance of comprehensive patient evaluation for CAR T-cell therapy candidacy

Recommendations

• Review individual patient characteristics carefully.
• Consider CAR T-cell therapy as a potential salvage or bridge to subsequent therapies.
• Discuss potential benefits and risks with patients, emphasizing long-term response potential.
• Integrate molecular and clinical factors in treatment decision-making.